Osteoporosis International

, Volume 16, Issue 5, pp 510–516 | Cite as

Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy

  • J.-M. Kaufman
  • E. Orwoll
  • S. Goemaere
  • J. San Martin
  • A. Hossain
  • G. P. Dalsky
  • R. Lindsay
  • B. H. Mitlak
Original Article

Abstract

Teriparatide (rhPTH[1-34]), a bone-forming agent for the treatment of osteoporosis, increases bone mineral density in men and women, and reduces the risk of fractures in women with osteoporosis. However, fracture efficacy has not yet been confirmed in men. Further, there is limited information on the effect of withdrawal of teriparatide. The purpose of this manuscript is to report on bone mineral density and vertebral fracture incidence during a 42-month observation period, from the baseline of the previously reported treatment study in men [1] through 30 months of posttreatment follow-up. Three hundred fifty-five men who were treated with once-daily self-injections of either placebo or 20 or 40 µg of teriparatide participated in the follow-up study. Bone mineral density gradually decreased following discontinuation of teriparatide therapy. However, the lumbar spine and total hip values remained significantly higher than baseline after 30 months of follow-up (p≤0.001). Antiresorptive treatment prevented the decline and tended to further increase bone mineral density. Lateral thoracic lumbar radiographs obtained at baseline and 18 months after discontinuation of teriparatide were available for 279 men. Of these men, 11.7% assigned to placebo, 5.4% treated with teriparatide 20 µg, and 6.0% treated with teriparatide 40 µg had an incident vertebral fracture. In the combined teriparatide treated groups vs placebo, the risk of vertebral fracture was reduced 51% (nonsignificant, p=0.07). The incidence of moderate or severe fractures was significantly reduced by 83% (p=0.01). In conclusion, men who received teriparatide and who may have received follow-up antiresorptive therapy had a decreased risk of moderate and severe vertebral fractures.

Keywords

Bone formation Bone mineral density Drug therapy Osteoporosis in men Teriparatide Vertebral fracture 

Notes

Acknowledgements

The authors acknowledge Mary Ellen Perron for preparation of the figures and editorial assistance, Amanda D. Clancy for statistical contributions to the study, Julie Satterwhite and Michael Heathman for technical assistance, and David W. Donley and Gerhardt Pohl for manuscript review. Funding: This work was supported by Eli Lilly and Company.

References

  1. 1.
    Orwoll E, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich G (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone mineral density in men with osteoporosis. J Bone Miner Res 18:9–17PubMedGoogle Scholar
  2. 2.
    European Perspective Osteoporosis Study Group (2002) Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 17:716–724PubMedGoogle Scholar
  3. 3.
    Van der Klift M, de Laet C, Mcclosky EV, Hofman A, Pols HA (2002) The incidence of vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res 17:1051–1056PubMedGoogle Scholar
  4. 4.
    Burger H, Van Daele PL, Grashuis K, Hofman A, Grobbee DE, Schutte HE, Birkenhager JC, Pols HA (1997) Vertebral deformities and functional impairment in men and women. J Bone Miner Res 12:152–157PubMedGoogle Scholar
  5. 5.
    Melton LJ III, Atkinson EJ, Cooper C, O’Fallon WM, Riggs BL (1999) Vertebral fractures predict subsequent fractures. Osteoporos Int 10:214–221CrossRefPubMedGoogle Scholar
  6. 6.
    Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878–882CrossRefPubMedGoogle Scholar
  7. 7.
    Johansson C, Black D, Johnell O, Oden A, Mellstrom D (1998) Bone mineral density is a predictor of survival. Calcif Tissue Int 63:190–196CrossRefPubMedGoogle Scholar
  8. 8.
    Van der Klift M, Pols HAP, Geleijnse JM, Van der Kup DAM, Hofman A, de Laet CEDH (2002) Bone mineral density and mortality in elderly men and women: The Rotterdam Study. Bone 30:643–648CrossRefPubMedGoogle Scholar
  9. 9.
    Gehlbach SH, Burge RT, Puleo E, Klar J (2003) Hospital care of osteoporosis-related vertebral fractures. Osteoporos Int 14:53–60CrossRefPubMedGoogle Scholar
  10. 10.
    Ray NF, Chan JK, Thamer M, Melton LJ III (1997) Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 12:24–35PubMedGoogle Scholar
  11. 11.
    Reid DM, Adami S, Devogelaer JP, Chines AA (2001) Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69:242–247CrossRefPubMedGoogle Scholar
  12. 12.
    Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–610CrossRefPubMedGoogle Scholar
  13. 13.
    Ho YV, Frauman AG, Thomson W, Seeman E (2000) Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos Int 11:98–101PubMedGoogle Scholar
  14. 14.
    Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP (2000) Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069–3076CrossRefPubMedGoogle Scholar
  15. 15.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRefPubMedGoogle Scholar
  16. 16.
    Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen CA, Reginster J-Y, Stepan JJ, Myers S, Mitlak BH (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatide [recombinant human parathyroid hormone (1-34)] in postmenopausal women with osteoporosis. Arch Intern Med 164:in pressGoogle Scholar
  17. 17.
    Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore M, Ma L, Nold JB (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312–321CrossRefPubMedGoogle Scholar
  18. 18.
    Tashjian AH, Chabner BA (2002) Clinical safety of recombinant human parathyroid hormone (1-34) in the treatment of osteoporosis in postmenopausal women and men (commentary). J Bone Miner Res 17:1151–1161PubMedGoogle Scholar
  19. 19.
    Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M (2004) Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 32:426–438CrossRefPubMedGoogle Scholar
  20. 20.
    Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148PubMedGoogle Scholar
  21. 21.
    Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129–2134CrossRefPubMedGoogle Scholar
  22. 22.
    Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215CrossRefPubMedGoogle Scholar
  23. 23.
    Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216–1226CrossRefPubMedGoogle Scholar
  24. 24.
    Papaioannou A, Watts NB, Kendler DL, Yuen CK, Adachi JD, Ferko N (2002) Diagnosis and management of vertebral fractures in elderly adults. Am J Med 113:220–228CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2004

Authors and Affiliations

  • J.-M. Kaufman
    • 1
    • 5
  • E. Orwoll
    • 2
  • S. Goemaere
    • 1
  • J. San Martin
    • 3
  • A. Hossain
    • 3
  • G. P. Dalsky
    • 3
  • R. Lindsay
    • 4
  • B. H. Mitlak
    • 3
  1. 1.Ghent University HospitalGhentBelgium
  2. 2.Oregon Health & Science University and VA Medical CenterPortlandUSA
  3. 3.Eli Lilly and CompanyIndianapolisUSA
  4. 4.Columbia UniversityNew YorkUSA
  5. 5.Department of EndocrinologyGhent University HospitalGhentBelgium

Personalised recommendations